Respondents with stage III melanoma prefer adjuvant immunotherapy that reduces their risk of recurrence, reduces treatment adverse events and costs less.

Almost three-quarters of respondents chose adjuvant immunotherapy over no adjuvant immunotherapy. Preferences were found to statistically differ by the amount of immunotherapy experience and being female; women were significantly less accepting of treatment. Respondents were willing to pay between AU$794 and AU$4266 (US$527–2833) depending on income, for adjuvant immunotherapy per year to reduce their risk of immediate death and recurrence by 1%.

Health policymakers should consider respondents’ trade-offs and remove financial barriers to enable access to effective therapies.